| Filed On | Filing |
|---|---|
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
BETHESDA, Md., November 10, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule thera... |
| 30 Oct 2026 |
Form 4: Weidner Jeanette, See Remarks
Granted 130,000 Stock Option (right to buy) |
| 30 Oct 2026 |
Form 3: Weidner Jeanette, See Remarks
No securities owned |
| 28 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Employment Agreement (“Agreement”) is effective as of October 28, 2026 (“Effective Date”), by and between Gain Therapeutics, Inc. (“Company”) and Jeanette Weidner (“Executive”). |
| 01 Oct 2026 |
8-K: Other Events
On October 1, 2026, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing the presentation of a poster at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seou... |
| 28 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 22, 2026, Gianluca Fuggetta, Senior Vice President of Finance, principal financial officer, and principal accounting officer of Gain Therapeutics, Inc. (the “Company”), notified the Company of his intention to resign from hi... |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
BETHESDA, Md., August 11, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapi... |
| 17 Jul 2026 |
Form 4: Goldstein Dov A Md, Director
Granted 25,000 Stock Option (right to buy) |
| 17 Jul 2026 |
Form 4: Nicaise Claude, Director
Granted 25,000 Stock Option (right to buy) |
| 17 Jul 2026 |
Form 4: Islam Khalid, Director
Granted 25,000 Stock Option (right to buy) |
| 17 Jul 2026 |
Form 4: Melincoff Gwen A, Director
Granted 25,000 Stock Option (right to buy) |
| 17 Jul 2026 |
Form 4: Riley Jeffrey Scott, Director
Granted 25,000 Stock Option (right to buy) |
| 17 Jul 2026 |
Form 4: Hasler Hans Peter, Director
Granted 25,000 Stock Option (right to buy) |
| 16 Jul 2026 |
8-K: Other Events
On July 16, 2026, Gain Therapeutics, Inc. (the “Company”) issued a press release and shareholder letter in which it announced, among other things, that its current cash and cash equivalents are anticipated to fund the Company’s operation... |
| 29 Jun 2026 |
8-K: Other Events
On June 29, 2026, Gain Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has authorized the Company’s Investigational New Drug application for GT-02287. FDA’s decision will allow initiation o... |
| 25 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 24, 2026, Gain Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”), at which a quorum was present. The matters voted on at the Annual Meeting were: (1) the election of seven directors... |
| 26 May 2026 |
8-K: Other Events
On May 26, 2026, Gain Therapeutics, Inc. (the “Company”) disclosed interim clinical and biomarker data from Part 2 (the nine-month extension) of its Phase 1b open-label clinical study of GT-02287 in patients with Parkinson’s disease with... |
| 11 May 2026 | 10-Q |
Loading...